AdaptHealth (AHCO) Insider III Buys 18,999 Shares

AdaptHealth Corp. (NasdaqCM:AHCO) saw insider buying activity as Williams David Solomon III purchased 18,999 shares on June 24, 2026. This transaction wasn't part of a pre-planned trading program and reflects a direct acquisition of shares.

Insider Buying and Selling at AdaptHealth Corp.

On June 24, 2026, Williams David Solomon III bought 18,999 shares of AdaptHealth Corp. The transaction wasn't pre-arranged under a Rule 10b5-1 plan. Other recent insider activities include Susan Weaver purchasing 18,999 shares on the same day. Additionally, Chief Operating Officer Daniel Edward McFadden acquired 20,134 shares on May 27, 2026. Meanwhile, Chief Commercial Officer Russell Schuster III sold 11,275 shares on June 1, 2026, under a pre-planned trading program.

Other Institutional Activity in AdaptHealth Corp.

Several institutional investors have also been active in AdaptHealth. OEP Capital Advisors, L.P. increased its holdings by 2,494,518 shares, bringing its total to 16,312,698 shares valued at approximately $194.1 million, representing an 18.1% increase. BlackRock, Inc. added 247,939 shares, ending with 15,939,953 shares valued at about $189.7 million, marking a 1.6% increase. Reinhart Partners, LLC. grew its stake by 1,981,198 shares to 10,081,983 shares, worth around $120 million, a 24.5% increase. Deerfield Management Company, L.P. and SkyKnight Capital, L.P. maintained their positions without changes.

AdaptHealth Corp. Stock Up 79.9%

As of Saturday, shares of AdaptHealth Corp. traded near $10.18. The company has a market capitalization of approximately $1.4 billion and a forward P/E ratio of 8.75, indicating expectations of future earnings growth. The stock's beta is 1.463, suggesting it is more volatile than the market. Over the past year, AdaptHealth's shares have ranged from a low of $8.51 to a high of $13.43. The stock's 50-day moving average is $10.99, while its 200-day moving average is $10.21.

Recent Earnings

AdaptHealth reported revenues of approximately $3.29 billion, reflecting a growth of 5.4%. However, the company is currently not profitable, with a net margin of -2.42% and a return on equity of -4.85%. The next earnings report is expected on August 4, 2026.

Analysts Set New Price Targets

On May 11, 2026, RBC Capital maintained its 'buy' rating for AdaptHealth with a price target of $15. Canaccord Genuity and UBS also maintained 'buy' ratings, with price targets of $16 and $14, respectively, both on May 6, 2026. The consensus among analysts is a 'buy' rating, with a mean target price of $14 based on eight analyst opinions.

About AdaptHealth Corp.

AdaptHealth Corp., headquartered in Conshohocken, Pennsylvania, is a healthcare company providing home medical equipment and related services. It operates through various segments, including Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. The company offers a range of medical devices and services, such as sleep therapy and diabetes management equipment. AdaptHealth serves Medicare, Medicaid, and commercial insurance beneficiaries across the United States.

Bottom Line

Insider buying by Williams David Solomon III suggests confidence in AdaptHealth Corp.'s prospects. The company, with a market cap of about $1.4 billion, operates in the healthcare sector, specializing in home medical equipment. While the company isn't currently profitable, its revenue growth and analyst support indicate potential for future performance. As always, 13F filings and insider transactions are backward-looking and may not reflect the current state of holdings.